Long-term prognostic value of baseline C-reactive protein in predicting recurrence of atrial fibrillation after electrical cardioversion

PACE - Pacing and Clinical Electrophysiology

Volumn 31, Issue 10, 2008, Pages 1272-1276

  Korantzopoulos, Panagiotis ^a   Kalantzi, Kallirroi ^a   Siogas, Konstantinos ^b   Goudevenos, John A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

Atrial fibrillation; Electrical cardioversion; Inflammation; C reactive protein; Recurrence

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SINUS RHYTHM;

ATRIAL FIBRILLATION; C-REACTIVE PROTEIN; ELECTRIC COUNTERSHOCK; FEMALE; GREECE; HUMANS; LONGITUDINAL STUDIES; MALE; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 51849161553     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2008.01177.x     Document Type: Article

References (19)

1. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008 92 : 17 40.
2. Korantzopoulos P, Kolettis TM, Goudevenos JA, Siogas K. Errors and pitfalls in the non-invasive management of atrial fibrillation. Int J Cardiol 2005 104 : 125 130.
3. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: Basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 2005 13 : 181 193.
4. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006 27 : 136 149.
5. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007 115 : 135 143.
6. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: A systematic review of the published data. J Am Coll Cardiol 2007 50 : 2021 2028.
7. Watson T, Kakar P, Lip GY. Cardioversion for atrial fibrillation: Does inflammation matter? Am J Cardiol 2007 99 : 1617 1618.
8. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-analysis. J Am Coll Cardiol 2007 49 : 1642 1648.
9. Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007 99 : 1421 1424.
10. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, Stakos D, Floros D, Papanas N, Chalikias G, et al. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 2006 97 : 659 661.
11. Fujiki A, Sakamoto T, Nishida K, Mizumaki K, Inoue H. Relation of interleukin-6 and C-reactive protein levels to sinus maintenance after pharmacological cardioversion in persistent atrial fibrillation. J Cardiovasc Pharmacol 2007 50 : 264 266.
12. Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 2007 99 : 1544 1548.
13. Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, Karanikis P, Pappa E, Siogas K, et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005 102 : 321 326.
14. Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fibrillation: A review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol 2007 18 : 1222 1228.
15. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008 126 : 160 170.
16. Korantzopoulos P, Kolettis TM, Kountouris E, Siogas K, Goudevenos JA. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? Int J Clin Pract 2005 59 : 881 885.
17. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM, Chlouverakis GI, et al. The role of the post cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 2008 94 : 200 204.
18. Cosgrave J, Foley JB, Bahadur K, Bennett K, Crean P, Walsh MJ. Inflammatory markers are not associated with outcomes following elective external cardioversion. Int J Cardiol 2006 110 : 373 377.
19. Buob A, Jung J, Siaplaouras S, Neuberger HR, Mewis C. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 2006 29 : 559 563.